Clinical Trial Update: Evaluation of Ablation Index and VISITAG™ (ABI-173) [NA]

View source ↗

Summary

This clinical trial update reports the completion of ABI-173 evaluating Ablation Index and VISITAG technology for paroxysmal atrial fibrillation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Atrial Fibrillation

Drugs mentioned

• Ablation Index and VISITAG (ABI-173)

Snippet

Sponsor: Biosense Webster, Inc. | Conditions: Paroxysmal Atrial Fibrillation | NA | Status: COMPLETED